Management called 2025 a strong year on the Q4 call. Core revenue is up 33% year-over-year. The growth is coming from two main places: * **Diagnostics:** Oncology units grew 29% in Q4 and MRD testing jumped 56% from the previous quarter. * **Data/Licensing:** This segment grew 69% in the quarter. Total contract value is now over $1.1 billion with net revenue retention at 126%. The CEO focused heavily on their data advantage, claiming access to 450 petabytes of data and connections to 5,500 hospitals. They are also ramping up compute power with new H200 and GB200 clusters. Guidance suggests average selling prices could increase by $500 by the end of 2026 as they transition to FDA-approved versions of their tests.